Now available IMJUDO®

IMJUDO® (tremelimumab-actl) is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)blocking antibody indicated:

• in combination with durvalumab, for the treatment of adult patients withunresectable hepatocellular carcinoma (uHCC). (1.1)
• in combination with durvalumab and platinum-based chemotherapy for thetreatment of adult patients with metastatic non-small cell lung cancer (NSCLC)with no sensitizing epidermal growth factor receptor (EGFR) mutation oranaplastic lymphoma kinase (ALK) genomic tumor aberrations. (1.2)

Please see full prescribing information here.